ADAM17 and rheumatoid arthritis: Since the limitations of the present study are that the number of enrolled patients is relatively small, future studies should be performed in the large number of RA patients to confirm the pathophysiological role of ADAM17 in the course of RA with biologics such as ABT or antagonists for TNF or IL-6.